Limited use of medicinal cannabis but for labeled indications after legalization

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 11, 2005, Pages 821-822

  Erkens, Joelle A ^a   Janse, A F C ^a   Herings, R M C ^a,b  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cannabis; Community pharmacy; Legalization; Survey

Indexed keywords

CANNABIS;

ARTICLE; CHRONIC PAIN; DRUG INDICATION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; LEGAL ASPECT; MAJOR CLINICAL STUDY; MALE; MEDICINAL PLANT; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MUSCLE STIFFNESS; NETHERLANDS; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RHEUMATIC DISEASE; SYMPTOM;

CANNABIS; COMMUNITY PHARMACY SERVICES; DRUG UTILIZATION REVIEW; FOLLOW-UP STUDIES; LEGISLATION, DRUG; NETHERLANDS; PLANT PREPARATIONS; PRESCRIPTIONS, DRUG; PROSPECTIVE STUDIES;

EID: 28044456526     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1152     Document Type: Article

References (4)

1. http://www.cannabisbureau.nl/pdf/CANNABIS_Patienteninformatietekst.pdf
2. Killestein J, Bet PM, van Loenen AC, Polman CH. [Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness]. Ned Tijdschr Geneeskd 2004; 148(48): 2374-2378.
3. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362(9395): 1517-1526.
4. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460): 253.